The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://pageoftoday.com/story6177373/retatrutide-vs-tirzepatide-a-comparative-analysis